Insights from 2024 ASCO® GI Annual Meeting


 

ASCO® GI 2024 Insights: "LIBRETTO-001 Study - Durable Efficacy of Selpercatinib in Patients With RET Fusion+ Solid Tumors (Focus on GI Tumors)"

45 views
March 5, 2024
Comments 0
Login to view comments. Click here to Login